January 13, 2024
2 min watch
Save
VIDEO: Harrow launches Vevye dry eye treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio video perspective, Mark L. Baum, chairman and CEO at Harrow, discusses the launch of Vevye ophthalmic solution for the treatment of dry eye disease, here at Hawaiian Eye 2024.
“We are talking about better bioavailabilty, onset of action that is fast for your patient, durability of effect — we have data going out to 56 weeks with continued improvement in signs and symptoms — and finally incredible tolerability,” Baum told Healio.
Vevye is a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, according to a press release from Harrow.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Baum reports being chairman and CEO of Harrow.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.